MOK

MAPK/MAK/MRK overlapping kinase

4,081 patent compounds predicted against MOK, 2,017 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5220954	0.49	11/20
SCHEMBL3336361	0.51	10/20
SCHEMBL3339873	0.50	10/20
SCHEMBL3869547	0.46	10/20
SCHEMBL4732598	0.56	9/20
SCHEMBL4731923	0.54	9/20
SCHEMBL5819962	0.51	9/20
SCHEMBL4139048	0.47	9/20
SCHEMBL4735359	0.53	8/20
SCHEMBL4317695	0.45	8/20
SCHEMBL5782943	0.40	8/20
SCHEMBL2927675	0.53	7/20
SCHEMBL4911258	0.49	7/20
SCHEMBL3713979	0.47	7/20
SCHEMBL946673	0.45	7/20
SCHEMBL2574195	0.44	7/20
SCHEMBL2923640	0.42	7/20
SCHEMBL4082535	0.39	7/20
SCHEMBL5755497	0.38	7/20
SCHEMBL5750675	0.36	7/20

Germline variants in MOK on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full MOK gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to MOK by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma	PHASE4	UNKNOWN
Clinical Evaluation of the Effect of Metformin in Sepsis	PHASE3	UNKNOWN
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.	PHASE2	UNKNOWN
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma	PHASE2	UNKNOWN
Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma	PHASE2	RECRUITING
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma	PHASE1/PHASE2	COMPLETED
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma	PHASE2	ACTIVE_NOT_RECRUITING
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations	PHASE2	RECRUITING
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant	PHASE2	RECRUITING
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma	PHASE2	COMPLETED
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma	PHASE1/PHASE2	COMPLETED
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	PHASE2	COMPLETED
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...	PHASE2	COMPLETED
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations	PHASE2	COMPLETED
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer	PHASE2	RECRUITING
Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate Capsule	PHASE2	NOT_YET_RECRUITING
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies	PHASE1/PHASE2	RECRUITING
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212	PHASE1	COMPLETED
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)	PHASE1	COMPLETED
Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma	PHASE1	ACTIVE_NOT_RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations	PHASE1	SUSPENDED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101	PHASE1	WITHDRAWN
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo	nan	UNKNOWN
RASopathy Biorepository	nan	RECRUITING
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING
Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection.	nan	COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation	nan	COMPLETED
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MOK binder may also engage these)

Protein	Name	Similarity
Q9WVS4	—	0.998	Q9WVS4 →
O54863	—	0.981	O54863 →
P49187	—	0.980	P49187 →
Q39050	—	0.977	Q39050 →
TSSK1B	Testis-specific serine/threonine-protein kinase 1	0.976	landscape →
A0A0J9UVX2	—	0.975	A0A0J9UVX2 →
P62205	—	0.975	P62205 →
Q28GW8	—	0.974	Q28GW8 →
Q91821	—	0.974	Q91821 →
Q61831	—	0.974	Q61831 →
Q61241	—	0.974	Q61241 →
Q3SZW1	—	0.973	Q3SZW1 →
MELK	Maternal embryonic leucine zipper kinase	0.973	landscape →
Q8BTH8	—	0.973	Q8BTH8 →
PLK2	Serine/threonine-protein kinase PLK2	0.972	landscape →
Q62762	—	0.972	Q62762 →
Q5ZJS0	—	0.971	Q5ZJS0 →
P47809	—	0.971	P47809 →
Q9Z265	—	0.971	Q9Z265 →
Q8BVP5	—	0.971	Q8BVP5 →
Q5R4L1	—	0.971	Q5R4L1 →
Q61846	—	0.971	Q61846 →
P40233	—	0.971	P40233 →
I1S050	—	0.971	I1S050 →
Q6NRT0	—	0.971	Q6NRT0 →
Q9R012	—	0.971	Q9R012 →
MAPK10	Mitogen-activated protein kinase 10	0.971	landscape →
Q6P5G0	—	0.970	Q6P5G0 →
TSSK2	Testis-specific serine/threonine-protein kinase 2	0.970	landscape →
P43294	—	0.970	P43294 →